Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Cagrilintide cycle length: what human studies ran

InvestigationalAHuman trial evidence
Short answer: there is no established Cagrilintide cycle length or break. The human studies below ran for set periods under monitoring; none tested repeated courses.

Treatment and follow-up in human studies

  1. Phase 2 monotherapy: 26 weeks of treatment plus 6 weeks of follow-up 1.
  2. Phase 2 type 2 diabetes: 32 weeks 3.
  3. Phase 3 REDEFINE 1, REDEFINE 2 and REIMAGINE 2: 68 weeks 4,5,6.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Cagrilintide combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Cagrilintide cycle length?
No. Human studies administered Cagrilintide for the periods listed on this page. Those are study durations; none tested an on-and-off schedule or a break.
What is the longest human study of Cagrilintide?
The durations are listed on this page with their sources; compare them directly rather than relying on a summary.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Cagrilintide dosing reference Full research page

References

  1. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial Lancet. 2021
  2. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial Lancet. 2021
  3. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial Lancet. 2023
  4. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1) N Engl J Med. 2025
  5. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2) N Engl J Med. 2025
  6. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study Lancet Diabetes Endocrinol. 2026
  7. Development of Cagrilintide, a Long-Acting Amylin Analogue J Med Chem. 2021
  8. Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors Nat Commun. 2025
  9. Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 EBioMedicine. 2025
  10. CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 Hypertension. 2026
  11. Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression Diabetes Obes Metab. 2026
  12. A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight (REDEFINE 1, NCT05567796) ClinicalTrials.gov. 2026
  13. Drugs@FDA application data queried through openFDA for cagrilintide (no matching application record returned on 23 October 2026) openFDA / Drugs@FDA. 2026
  14. PubChem compound record for cagrilintide (CID 171397054; CAS 1415456-99-3) PubChem. 2026
  15. International Standard: Prohibited List 2026 World Anti-Doping Agency. 2026
  16. Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity (registry results: participant flow group descriptions) ClinicalTrials.gov. 2023